Showing 1721-1730 of 2038 results for "".
- Myze Launches 'The Daily Lid Wipe' for Eyelid Hygienehttps://modernod.com/news/myze-launches-the-daily-lid-wipe-to-elevate-daily-eye-care-partnering-with-leading-eye-health-experts/2482543/In a move to prioritize eyelid hygiene and make it a core component of everyday self-care routine, myze has unveiled its first branded product, The Daily Lid Wipe. The Daily Lid Wipe, formulated with input from dry eye experts Laura M. Periman, MD, and Cecelia Koett
- Harrow Secures Medicare Part D Market Access for Vevyehttps://modernod.com/news/harrow-secures-medicare-part-d-market-access-for-vevye/2482535/Harrow announced that beginning January 1, 2025, Harrow’s dry eye disease treatment, Vevye, will be included in the formularies of major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors provide coverage for more tha
- Cencora Acquires Retina Consultants of Americahttps://modernod.com/news/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america/2482528/Contract research organization Cencora has entered into a definitive agreement to acquire Retina Consultants of America (RCA), a management services organization (MSO) of retina specialists, from Webster Equity Partners. Cencora, formerly known as AmerisourceBergen, will acquire RC
- EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy Duravyuhttps://modernod.com/news/eyepoint-pharmaceuticals-doses-first-patient-in-phase-3-lugano-trial-for-wet-amd-therapy-duravyu/2482512/EyePoint Pharmaceuticals announced dosing of the first patient in its phase 3 LUGANO clinical trial of Duravyu. This investigational sustained delivery therapy, formerly known as EYP-1901, aims to treat wet age-related macular degeneration (AMD) using a patent-protected formulation of vorolanib,
- Google’s Diabetic Retinopathy AI Model Licensed for Use in India and Thailandhttps://modernod.com/news/googles-diabetic-retinopathy-ai-model-licensed-for-use-in-india-and-thailand/2482497/Google announced the licensing of its diabetic retinopathy artificial intelligence (AI) model to healthcare providers and health-tech partners. According to Google, during the next 10 years, Forus Health, AuroLab, and Perceptra will aim to deliver a combined 6 million AI-supported scree
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitishttps://modernod.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/Marinomed Biotech has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis. The results, now published in the peer-reviewed journal Clinical Ophthalmology, indicate that Tacrosolv, formulated usin
- Staar Opens New Experience Center to Meet Growing Surgeon Demandhttps://modernod.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/Staar Surgical announced the expansion of its Staar Surgical Experience Center near John Wayne Airport (SNA) in Lake Forest, California. The new center aims to provide comprehensive, hands-on training and education in lens-based vision correction. Staar says the 
- PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Boardhttps://modernod.com/news/pulsesight-therapeutics-establishes-international-scientific-and-clinical-advisory-board/2482424/PulseSight Therapeutics announced the formation of a Scientific and Clinical Advisory Board (SAB) composed of internationally recognized experts in ophthalmology from Europe, the US, and Australia with extensive experience in both fundamental and clinical research in retinal and macular
- Samsara Vision Promotes Jason Herod to Chief Commercial Officerhttps://modernod.com/news/samsara-vision-promotes-jason-herod-to-chief-commercial-officer/2482421/Samsara Vision announced that Jason Herod, formerly Vice President Commercial, International Markets, has been promoted to Chief Commercial Officer (CCO), effective August 15, 2024. Mr. Herod joined Samsara Vision in August 2021, bringing with him over 24 years of extensive experi